Press Releases August 13, 2026 01:15 AM

Robinhood Ventures Fund II (RVII) Announces Pricing of Initial Public Offering

Robinhood Ventures Fund II prices IPO on NYSE to provide retail investors early-stage private company exposure

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
RVII

Robinhood Ventures Fund II has priced its initial public offering of 8 million shares at $25 each on the NYSE under ticker RVII. The fund aims to give retail investors access to a diversified portfolio of early-stage private companies, particularly those linked to Y Combinator. The IPO is led by major underwriters and is expected to close mid-August 2026.

Robinhood Ventures Fund II (RVII) Announces Pricing of Initial Public Offering
RVII
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • RVII is a business development company providing retail investors exposure to early-stage private companies.
  • The IPO priced at $25 per share with potential to raise up to $255.5 million including underwriter options.
  • Focus on companies involved or affiliated with Y Combinator startup accelerator program.
  • Sectors impacted include venture capital, private equity, and retail investment markets.


MENLO PARK, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Today, Robinhood Ventures Fund II (RVII) announced the pricing of its initial public offering of 8,000,000 common shares of beneficial interest at an initial public offering price of $25.00 per share. This brings the total size of the Fund to $225.5 million, or up to $255.5 million if the underwriter’s option to purchase additional common shares is exercised in full. The total fund size is calculated before deducting the sales load and offering expenses.

The shares are expected to begin trading on the New York Stock Exchange (NYSE) on Aug. 13, 2026 under the symbol RVII, and the offering is expected to close on Aug. 14, 2026, subject to the satisfaction of customary closing conditions.

RVII has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 common shares of beneficial interest from RVII at the same price as the initial offering price, less underwriting discounts and commissions.

RVII is a business development company (“BDC”), a type of closed-end fund, that provides retail investors exposure to a diversified portfolio of private companies in their earliest stages. Investors can learn more by reading the registration statement.

Goldman Sachs & Co. LLC is the lead bookrunner for the offering. Citigroup, J.P. Morgan, UBS Investment Bank, and Wells Fargo Securities are joint bookrunners for the offering.

A registration statement relating to the sale of common shares of beneficial interest of RVII was declared effective by the Securities and Exchange Commission on Aug. 12, 2026.

This offering is being made only by means of a final prospectus. Copies of the final prospectus related to the offering, when available, may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526 or by emailing [email protected]; J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: [email protected] and [email protected]; Citigroup, ℅ Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel:800-831-9146); Wells Fargo Securities LLC, 608 2nd Avenue South, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to [email protected]; or UBS Securities LLC, Attention: Equity Syndicate, 11 Madison Avenue, New York, NY 10010, by telephone at (888) 827-7275, or by email at [email protected]. Investors are advised to carefully consider the investment objectives, risks and charges and expenses of RVII before investing. The prospectus, which contains this and other information about RVII, should be read carefully before investing.

This press release is being made pursuant to, and in accordance with, Rule 134 under the Securities Act of 1933, as amended, and shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Disclosures:

An investment in Robinhood Ventures Fund II is speculative and involves a high degree of risk with substantial risk of loss.

Robinhood Ventures is the investment adviser for RVII. Robinhood Ventures is the dba name for Robinhood Ventures DE, LLC. Robinhood Ventures is an SEC-registered investment adviser and a wholly owned subsidiary of Robinhood Markets, Inc.

Forward-Looking Statements

This communication includes “forward looking statements,” including with respect to the completion of RVII’s initial public offering and the expected listing of RVII’s shares on the New York Stock Exchange under the symbol “RVII.” These statements also include statements regarding RVII’s objectives to provide retail investors exposure to a diversified portfolio of private companies in their earliest stages, to make seed investments in companies across sectors, to focus on companies that are current or previous participants in the Y Combinator startup accelerator program or companies with a founder or co-founder that participated in the program, and other statements that are not historical facts. You can sometimes identify forward-looking statements through the use of words or phrases such as “will,” “expect,” “anticipated,” “aim,” “intended,” or similar words and expressions of the future. Forward-looking statements involve known and unknown risks, uncertainties and assumptions, including the risks outlined under “Risks” in the preliminary prospectus and elsewhere in RVII’s filings with the SEC, which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement. RVII and Robinhood have no obligation, and do not undertake any obligation, to update or revise any forward-looking statement made in this communication to reflect changes since the date of this communication, except as required by law.

5838116

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3996552d-6798-448d-8a01-f28794b80be2


Risks

  • Investment in RVII is speculative with high risk of loss inherent in seed-stage company investments.
  • Market volatility and performance of private startups could affect fund returns.
  • Potential lack of liquidity typical of closed-end funds and early-stage investments may impact investor exit options.

More from Press Releases

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older Aug 13, 2026 Duolingo Invests in World-Class Motion Design with Acquisition of Animade Aug 13, 2026 Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update Aug 12, 2026 Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants Aug 12, 2026 Global Water Resources Reports Second Quarter 2026 Results Aug 12, 2026